An Overview of Dapagliflozin

Abstract

Type 2 diabetes, a chronic, progressive condition, causes hyperglycemia in the heart, liver, skeletal muscle, and adipose tissue. The latest forecasts show 592 million diabetics globally by 2035, up from 382 million in 2013. A new line of medicines blocks the kidney-based transporter protein sodium glucose co- transporter-2 (SGLT2) independently of insulin, complementing insulin treatment. Dapagliflozin (Forxiga) is a new EU-approved type 2 diabetes medication. This insulin-dependent process boosts urine glucose excretion. By specifically and potentially inhibiting SGLT2, dapagliflozin decreases blood glucose without insulin. Dapagliflozin had no clinically meaningful pharmacokinetic interactions with metformin, pioglitazone, sitagliptin, or glimepiride in healthy volunteers. The principal findings of clinical trials employing dapagliflozin to treat type 2 diabetes showed that the prescribed dosage (10 mg/day) was beneficial. Dapagliflozin works best with type 2 diabetes and cardiovascular disease or risk factors.